pillbase.ru

Daliresp

Active substance: roflumilast

TABLET · ROFLUMILAST 250 ug/1

United StatesActive

Marketing holder: AstraZeneca Pharmaceuticals LP

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 1
  • Даксас
    таблетки покрытые пленочной оболочкой, 0.5 мг (original in Russian, GRLS)
    ЛП-000573
    АстраЗенека АБ
EU 3
  • Daxas
    roflumilast
    EMEA/H/C/001179
    AstraZeneca AB
  • Daliresp
    roflumilast
    EMEA/H/C/002398
    AstraZeneca AB
  • Libertek
    roflumilast
    EMEA/H/C/002399
    AstraZeneca AB
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c5-0088-7dc0-9963-7afbcab3ab13;count=1 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-949a-7954-af4c-2b433822f0ad,01a1208c-c907-707d-a584-e4b8f4c0ba3f,01a1208c-f534-78cc-98e3-aa5300dfccfa,01a1208c-f54f-7964-af58-a9487b00fea1,01a1208d-51ef-7ece-ae17-3cec2c718d8f;count=33 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
0310-0088
Registration status
Active
Dispensing
Prescription only
Route
ORAL
Sources
  • product · openFDA NDC · 0310-0088 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 0310-0088 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 0310-0088 · Verified 2026-10-09 · open in source